Reaction
Immunoglobulins Decreased reporting signals
As of the last recalculation, Immunoglobulins Decreased appears in 1,349 FAERS reports alongside 33 co-occurring drug terms. The strongest observed disproportionality signal is HUMAN IMMUNOGLOBULIN G (PRR 106.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Human Immunoglobulin G | 129 | 106.6 | 107.2 |
| Ocrelizumab | 153 | 42.8 | 42.9 |
| Bendamustine Hcl | 29 | 29.5 | 29.5 |
| Diphenhydramine Hydrochloride Capsule, Liquid Filled | 33 | 24.4 | 24.4 |
| Liothyronine Sodium | 12 | 21.4 | 21.5 |
| Amphotericin B | 17 | 21.2 | 21.2 |
| Ofatumumab | 44 | 21.1 | 21.1 |
| Axicabtagene Ciloleucel | 12 | 18.9 | 18.9 |
| Blinatumomab | 11 | 16.4 | 16.4 |
| Adrenalinum | 40 | 15.3 | 15.3 |
| Carfilzomib | 27 | 15.0 | 15.0 |
| Valacyclovir | 37 | 14.0 | 14.1 |
| Diphenhydramine | 53 | 13.4 | 13.4 |
| Rituximab | 162 | 13.3 | 13.3 |
| Daratumumab | 32 | 12.6 | 12.6 |
| Fludarabine Phosphate | 30 | 12.0 | 12.0 |
| Ixazomib | 22 | 12.0 | 12.0 |
| Prochlorperazine Maleate | 7 | 11.8 | 11.8 |
| Zonisamide | 11 | 11.6 | 11.6 |
| Ibrutinib | 58 | 11.5 | 11.5 |
| Acalabrutinib | 9 | 11.5 | 11.5 |
| Obinutuzumab | 12 | 11.3 | 11.4 |
| Epinephrine | 41 | 9.9 | 9.9 |
| Valacyclovir Hydrochloride | 44 | 9.9 | 9.9 |
| Belimumab | 20 | 9.9 | 9.9 |
| Polatuzumab Vedotin | 6 | 9.5 | 9.5 |
| Thalidomide | 22 | 9.4 | 9.4 |
| Siponimod | 4 | 6.9 | 6.9 |
| Venetoclax | 23 | 5.8 | 5.8 |
| Tapentadol Hydrochloride | 8 | 3.7 | 3.7 |
| Rimegepant Sulfate | 3 | 3.7 | 3.7 |
| Lenalidomide | 81 | 3.1 | 3.1 |
| Pomalidomide | 20 | 3.0 | 3.0 |